Related Experiment Video
Updated: Nov 12, 2025
03:55
Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma
Published on: December 29, 2023
796
[Rebamipide: evidence base for use in gastroenterology]
1Yevdokimov Moscow State University of Medicine and Dentistry.
Terapevticheskii Arkhiv
|March 15, 2021
Summary
Rebamipide is a cytoprotective medication that safeguards the gastrointestinal tract. Clinical studies show its effectiveness in treating various esophageal, stomach, and intestinal diseases.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Rebamipide is a well-established cytoprotective drug with a 30-year history in clinical practice.
- It is utilized for its protective effects on the gastrointestinal mucosa.
Purpose of the Study:
- To review and summarize key clinical findings on rebamipide's efficacy.
- To consolidate evidence regarding its application across different gastrointestinal segments.
Main Methods:
- Systematic review of relevant clinical studies.
- Analysis of data from trials investigating rebamipide in various gastrointestinal conditions.
Main Results:
- Rebamipide demonstrates therapeutic benefits in diseases affecting the esophagus, stomach, small intestine, and large intestine.
- Clinical evidence supports its role in managing a range of gastrointestinal disorders.
Conclusions:
- Rebamipide is a valuable therapeutic agent for diverse gastrointestinal conditions.
- Its cytoprotective properties contribute to its effectiveness in gastroenterology.
Keywords:
Helicobacter pyloriNSAID enteropathyNSAID gastropathychronic gastritiscorrosive esophagitisfunctional dyspepsiagastroesophageal reflux diseasepeptic ulcer diseaserebamipideulcerative colitisMore Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
280
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
280
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
572
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
572
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
493
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
493
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
350
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
350
01:17Drugs for Treatment of Diarrhea-Predominant IBS
418
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
418
01:21Drugs for Treatment of Constipation-Predominant IBS
453
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
453